First-in-class diabetes drug launches in UK

A novel class of blood glucose-lowering treatment for type 2 diabetes has launched in the UK after gaining European approval, offering GPs new treatment options.

Finger prick: new class of diabetes drugs approved
Finger prick: new class of diabetes drugs approved

Dapagliflozin (Forxiga) belongs to a new drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by reducing the amount of glucose reabsorbed by the kidney.

This means it can be prescribed alongside other glucose-lowering drugs, including insulin, when these treatments along with changes in diet and exercise do not provide sufficient blood glucose control. It can also be used as monotherapy when metformin is not tolerated.

A study found reductions in blood glucose with dapagliflozin were similar to those in patients treated with a sulphonylurea plus metformin.

Research has also suggested dapagliflozin plus metformin can also encourage weight loss averaging 3.7kg over two years, compared with weight gain of 1.36kg among patients on sulphonylurea plus metformin.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GPs yet to receive thousands of pounds in QOF pay amid PCSE problems, says BMA

GPs yet to receive thousands of pounds in QOF pay amid PCSE problems, says BMA

Around 1,000 GP practices have yet to receive QOF payments potentially worth up to...

Vaccine gap leaves parts of England more exposed amid Delta variant surge

Vaccine gap leaves parts of England more exposed amid Delta variant surge

A far higher proportion of people have received both doses of COVID-19 vaccine in...

Bullying has continued in LMCs post-Romney review, GP whistleblower warns

Bullying has continued in LMCs post-Romney review, GP whistleblower warns

Bullying and sexism are continuing within local medical committees two years after...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...